|
审核状态: Project audit state: |
通过审核 Successful |
|
注册号: Registration number: |
ChiCTR-OOC-15007681 |
|
最近更新日期: Date of Last Refreshed on: |
2015-12-31 11:07:40 |
|
注册时间: Date of Registration: |
2015-12-28 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
中国住院患者静脉血栓栓塞症风险特征的调查 |
|
Public title: |
Identification of Chinese Hospitalized Patients’ Risk Profile for Venous Thromboembolism |
|
注册题目简写: |
DissolVE 1 |
|
English Acronym: |
DissolVE 1 |
|
研究课题的正式科学名称: |
中国住院患者静脉血栓栓塞症风险特征的调查 |
|
Scientific title: |
Identification of Chinese Hospitalized Patients’ Risk Profile for Venous Thromboembolism |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
U1111-1178-0079 |
|
申请注册联系人: |
赛诺菲 |
研究负责人: |
郭书剑 |
|
Applicant: |
Sanofi |
Study leader: |
Shujian Guo |
|
申请注册联系人电话: Applicant telephone: |
+86 21 22266622 |
研究负责人电话:
Study leader's |
+86 10 65634705 |
|
申请注册联系人传真 : Applicant Fax: |
+86 21 60123538 |
研究负责人传真: Study leader's fax: |
+86 10 85215223 |
|
申请注册联系人电子邮件: Applicant E-mail: |
contact-us.cn@sanofi.com |
研究负责人电子邮件: Study leader's E-mail: |
Shujian.Guo@Sanofi.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
上海市静安区延安中路1228号静安嘉里中心办公楼3座19楼 |
研究负责人通讯地址: |
北京市朝阳区建国路108号海航实业大厦2层 |
|
Applicant address: |
19F Tower III, Kerry Center, 1228 Middle Yan'an Road, Jing'an District, Shanghai |
Study leader's address: |
2F, HNA Building, 108 Jianguo Road, Chaoyang District. Beijing |
|
申请注册联系人邮政编码: Applicant postcode: |
200040 |
研究负责人邮政编码: Study leader's postcode: |
100022 |
|
申请人所在单位: |
赛诺菲(中国)投资有限公司上海分公司 |
||
|
Applicant's institution: |
SANOFI (CHINA) INVESTMENT CO., LTD. SHANGHAI BRANCH |
||
|
研究负责人所在单位: |
|
||
|
Affiliation of the Leader: |
|
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
S2015-094-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
中国人民解放军总医院医学伦理委员会 |
||
|
Name of the ethic committee: |
Ethic Committee of Chinese PLA general hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2015-12-08 00:00:00 | ||
|
伦理委员会联系人: |
|
||
|
Contact Name of the ethic committee: |
|
||
|
伦理委员会联系地址: |
|
||
|
Contact Address of the ethic committee: |
|
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
||
|
研究实施负责(组长)单位: |
中国人民解放军总医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Chinese PLA general hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
北京市海淀区复兴路28号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 28 Renaissance Road, Haidian District, Beijing |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
赛诺菲(北京)制药有限公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
Sanofi (Beijing) Pharmaceutical Co., Ltd. |
||||||||||||||||||||||
|
研究疾病: |
静脉血栓 |
||||||||||||||||||||||
|
Target disease: |
Venous Thromboembolism |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
其它 | ||||||||||||||||||||||
|
Study phase: |
N/A |
||||||||||||||||||||||
|
研究设计: |
队列研究 |
||||||||||||||||||||||
|
Study design: |
Cohort study |
||||||||||||||||||||||
|
研究目的: |
主要目的:在诊断出症状性VTE 前的6 周内有住院史并在当时医疗环境下处于VTE风险的患者中,确定接受恰当预防的患者的百分数 调查VTE诊断后的3个月内症状性VTE的治疗模式 次要目的:提供符合实际的健康数据并回答以下问题:1.症状性VTE患者在住院期间携带VTE 危险因素的比例是多少? 2. 既往内科或外科住院期间,中国人急性VTE 患者携带的风险因素中最常见的风险因素是什么? 评估3 个月随访期间接受VTE 治疗的中国患者的死亡率、VTE 复发性事件、肝素诱导性血小板减少症(HIT)、出血事件的发生率. 其他:入组和3 个月随访期内,如果患者因为VTE、抗凝相关出血事件或HIT而住院,则评价医疗成本和住院时间 入组和3 个月随访期内,根据欧洲五维健康量表(EQ-5D)评价患者健康情况 |
||||||||||||||||||||||
|
Objectives of Study: |
Primary: To identify the percentage of patients who received appropriate prophylaxis among those who have experienced a hospital setting within previous 6 weeks prior to the diagnosis of symptomatic venous thromboembolism (VTE) and were at risk of VTE during their medical setting; To investigate the treatment pattern of symptomatic VTE during 3 months after VTE diagnosis. Secondary: To provide real life data and answer the questions below: 1. What proportion of the symptomatic VTE patients within a medical setting were at risk of VTE during their hospital setting? 2. What are the most frequent pre-existing risk factors in Chinese acute VTE patients among all risks factors of VTE during their pervious medical or surgical hospitalization period? To assess the rates of mortality, VTE recurrent events, Heparin-induced-thrombocytopenia (HIT), bleeding events among Chinese patients treated for VTE during a 3-month follow up; Others: To evaluate the medical cost and hospitalization days if the patients are admitted to hospital due to VTE, anticoagulation related bleeding events or HIT at enrollment and during the 3-month follow-up; To evaluate the patients health outcome based on EQ-5D at enrollment and during 3-month follow-up. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
经客观性检查证实患有急性症状性VTE 的患者 |
||||||||||||||||||||||
|
Inclusion criteria |
1. Patients with acute symptomatic VTE, confirmed with objective test; |
||||||||||||||||||||||
|
排除标准: |
当前正在参与一项干预性临床试验的患者 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Patients who are currently participating in a interventional clinical trial; |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2016-01-14 00:00:00至 To 2018-08-21 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2016-01-21 00:00:00 至 To 2017-01-21 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
NA |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
|
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
|
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
|
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
|
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
|
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |